Inhibitor development in previously untreated patients (PUPs) with hemophilia A and B: A prospective 23-year-follow-up

被引：0
|
作者：
Ettingshausen, CE
Zyschka, A
Oldenburg, J
Saguer, IM
Ehrenforth, S
Kreuz, W
Goethe, JW
机构：
[1] JW Goethe Univ Hosp, Dept Pediat, Frankfurt, Germany
[2] Univ Wurzburg, Inst Human Genet, D-8700 Wurzburg, Germany
来源：
THROMBOSIS AND HAEMOSTASIS | 1999年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1300
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [21] DETERMINING INHIBITOR-DEVELOPMENT RISK IN PREVIOUSLY UNTREATED HEMOPHILIA-A PATIENTS TREATED (PUPS) WITH RECOMBINANT FACTOR-VIII (RECOMBINATE(TM))
    LEE, ML
    COURTER, S
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 856 - 856
  • [22] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B
    Shapiro, A
    Abshire, T
    Gill, J
    Kisker, T
    Pasi, J
    Rodriguez, D
    Courter, S
    BLOOD, 1998, 92 (10) : 356A - 356A
  • [23] Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B
    Nolan, Beatrice
    Klukowska, Anna
    Shapiro, Amy
    Rauch, Antoine
    Recht, Michael
    Ragni, Margaret
    Curtin, Julie
    Gunawardena, Sriya
    Mukhopadhyay, Sutirtha
    Jayawardene, Deepthi
    Winding, Bent
    Fischer, Kathelijn
    Liesner, Raina
    BLOOD ADVANCES, 2021, 5 (13) : 2732 - 2739
  • [24] Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
    Male, Christoph
    Andersson, Nadine G.
    Rafowicz, Anne
    Liesner, R. I.
    Kurnik, Karin
    Fischer, Kathelijn
    Platokouki, Helen
    Santagostino, Elena
    Chambost, Herve
    Nolan, Beatrice
    Koeigs, Christoph
    Kenet, Gili
    Ljung, Rolf
    van den Berg, H. Marijke
    HAEMATOLOGICA, 2021, 106 (01) : 123 - 129
  • [25] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the RODIN study
    Gouw, S. C.
    Van den Berg, M.
    Auerswald, G.
    Carcao, M.
    Chalmers, E.
    Chambost, H.
    Fischer, K.
    Kurnik, K.
    Liesner, R.
    Petrini, P.
    Platokouki, H.
    Altisent, C.
    Oldenburg, J.
    Nolan, B.
    Perez Garido, R.
    Rafowicz, A.
    Williams, M.
    Van der Bom, J. G.
    HAEMOPHILIA, 2012, 18 : 3 - 4
  • [26] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
    Masashi Taki
    Katsuyuki Fukutake
    Tadashi Matsushita
    Keiji Nogami
    Midori Shima
    Akira Yoshioka
    Junki Takamatsu
    Morio Arai
    Hiroshi Takagi
    Haruhiko Uchikawa
    Werner Engl
    Akira Shirahata
    International Journal of Hematology, 2019, 109 : 70 - 78
  • [27] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
    Taki, Masashi
    Fukutake, Katsuyuki
    Matsushita, Tadashi
    Nogami, Keiji
    Shima, Midori
    Yoshioka, Akira
    Takamatsu, Junki
    Arai, Morio
    Takagi, Hiroshi
    Uchikawa, Haruhiko
    Engl, Werner
    Shirahata, Akira
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 70 - 78
  • [28] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: The RODIN study
    Gouw, S.
    Van den Berg, H.
    Van der Bom, J.
    HAEMOPHILIA, 2012, 18 : 89 - 89
  • [29] RECOMBINANT FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    PEDIATRIC RESEARCH, 1995, 37 (04) : A161 - A161
  • [30] Incidence of factor VIII inhibitor in Korean previously untreated hemophilia A patients
    Yoo, Ki Young
    Park, Young Shil
    Kim, Ji Yoon
    HAEMOPHILIA, 2018, 24 : 28 - 28
12345